Assessing the Ability of the T-SPOT®.TB Test (IQ) (IQ)
Assessing the Ability of the T-SPOT®.TB Test to Identify Those at Risk of Active Mycobacterium Tuberculosis Infection Using the Normalized Tuberculosis (TB) Specific Lymphocyte Response.
Sponsor: Oxford Immunotec
Listed as NCT03973970, this observational or N/A phase trial focuses on Tuberculosis and remains completed. Sponsored by Oxford Immunotec, it has been updated 11 times since 2019, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Mar 2021 — Dec 2021 [monthly]
Completed
-
Jan 2021 — Mar 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting
Status: Suspended → Active Not Recruiting
-
May 2020 — Aug 2020 [monthly]
Suspended
Status: Recruiting → Suspended
-
Nov 2019 — May 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting
-
Jul 2019 — Sep 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Oxford Immunotec
For direct contact, visit the study record on ClinicalTrials.gov .